Expert opinion on monitoring symptomatic hereditary transthyretin-mediated amyloidosis and assessment of disease progression
Abstract Background Hereditary transthyretin-mediated amyloidosis, also known as ATTRv amyloidosis (v for variant), is a rare, autosomal dominant, fatal disease, in which systemic amyloid progressively impairs multiple organs, leading to disability and death. The recent approval of disease-modifying...
Main Authors: | David Adams, Vincent Algalarrondo, Michael Polydefkis, Nitasha Sarswat, Michel S. Slama, Jose Nativi-Nicolau |
---|---|
Format: | Article |
Language: | English |
Published: |
BMC
2021-10-01
|
Series: | Orphanet Journal of Rare Diseases |
Subjects: | |
Online Access: | https://doi.org/10.1186/s13023-021-01960-9 |
Similar Items
-
Avoiding misdiagnosis: expert consensus recommendations for the suspicion and diagnosis of transthyretin amyloidosis for the general practitioner
by: Morie Gertz, et al.
Published: (2020-09-01) -
Advances in the treatment of hereditary transthyretin amyloidosis: A review
by: Morie A. Gertz, et al.
Published: (2019-09-01) -
A Clinical Case of the Hereditary Transthyretin Amyloidosis
by: E. V. Reznik, et al.
Published: (2021-05-01) -
Tegsedi (Inotersen): An Antisense Oligonucleotide Approved for the Treatment of Adult Patients with Hereditary Transthyretin Amyloidosis
by: Luís Gales
Published: (2019-05-01) -
Ocular Involvement in Hereditary Amyloidosis
by: Angelo Maria Minnella, et al.
Published: (2021-06-01)